ECM-Receptor Regulatory Network and Its Prognostic Role in Colorectal Cancer.
ECM–receptor
TCGA-COAD
TCGA-READ
colorectal cancer
network analysis
Journal
Frontiers in genetics
ISSN: 1664-8021
Titre abrégé: Front Genet
Pays: Switzerland
ID NLM: 101560621
Informations de publication
Date de publication:
2021
2021
Historique:
received:
24
09
2021
accepted:
05
11
2021
entrez:
23
12
2021
pubmed:
24
12
2021
medline:
24
12
2021
Statut:
epublish
Résumé
Interactions of the extracellular matrix (ECM) and cellular receptors constitute one of the crucial pathways involved in colorectal cancer progression and metastasis. With the use of bioinformatics analysis, we comprehensively evaluated the prognostic information concentrated in the genes from this pathway. First, we constructed a ECM-receptor regulatory network by integrating the transcription factor (TF) and 5'-isomiR interaction databases with mRNA/miRNA-seq data from The Cancer Genome Atlas Colon Adenocarcinoma (TCGA-COAD). Notably, one-third of interactions mediated by 5'-isomiRs was represented by noncanonical isomiRs (isomiRs, whose 5'-end sequence did not match with the canonical miRBase version). Then, exhaustive search-based feature selection was used to fit prognostic signatures composed of nodes from the network for overall survival prediction. Two reliable prognostic signatures were identified and validated on the independent The Cancer Genome Atlas Rectum Adenocarcinoma (TCGA-READ) cohort. The first signature was made up by six genes, directly involved in ECM-receptor interaction: AGRN, DAG1, FN1, ITGA5, THBS3, and TNC (concordance index 0.61, logrank test
Identifiants
pubmed: 34938324
doi: 10.3389/fgene.2021.782699
pii: 782699
pmc: PMC8685507
doi:
Types de publication
Journal Article
Langues
eng
Pagination
782699Informations de copyright
Copyright © 2021 Nersisyan, Novosad, Engibaryan, Ushkaryov, Nikulin and Tonevitsky.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Oncol. 2019 Sep 18;9:924
pubmed: 31620371
Mol Ther. 2020 Jan 8;28(1):157-170
pubmed: 31636041
Oncol Rep. 2019 Sep;42(3):923-936
pubmed: 31322253
Onco Targets Ther. 2019 Nov 14;12:9651-9661
pubmed: 31814731
Genome Res. 2008 Apr;18(4):610-21
pubmed: 18285502
Mol Biol (Mosk). 2018 May-Jun;52(3):411-434
pubmed: 29989574
Nucleic Acids Res. 2021 Jan 8;49(D1):D545-D551
pubmed: 33125081
Anticancer Res. 2016 Sep;36(9):4559-67
pubmed: 27630296
BMC Med Genomics. 2018 Feb 13;11(Suppl 1):9
pubmed: 29504916
Onco Targets Ther. 2020 Dec 07;13:12521-12538
pubmed: 33324071
Biochimie. 2020 Jul;174:107-116
pubmed: 32334043
Front Genet. 2021 May 31;12:662468
pubmed: 34135940
Oncol Lett. 2017 Jun;13(6):4571-4576
pubmed: 28588719
Nucleic Acids Res. 2015 Oct 30;43(19):9158-75
pubmed: 26400174
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Adv Drug Deliv Rev. 2016 Feb 1;97:4-27
pubmed: 26562801
Carbohydr Res. 2014 May 7;389:39-45
pubmed: 24491280
RNA Biol. 2021 Oct 15;18(sup1):430-438
pubmed: 34286662
Nucleic Acids Res. 2019 Jan 8;47(D1):D253-D258
pubmed: 30371815
Biochem Biophys Res Commun. 2009 Dec 18;390(3):1061-5
pubmed: 19861116
Cell Tissue Res. 2010 Jan;339(1):269-80
pubmed: 19693543
Nat Methods. 2020 Mar;17(3):261-272
pubmed: 32015543
Biomed Pharmacother. 2018 Oct;106:1046-1051
pubmed: 30119170
Proc Natl Acad Sci U S A. 2012 Sep 25;109(39):E2595-604
pubmed: 22923691
Am J Pathol. 2011 Jul;179(1):380-90
pubmed: 21703417
Nucleic Acids Res. 2014 Aug;42(14):9424-35
pubmed: 25056318
Oncotarget. 2014 Sep 30;5(18):8790-802
pubmed: 25229428
J Pathol. 2008 Feb;214(3):357-67
pubmed: 18044827
J Biomed Inform. 2012 Apr;45(2):350-62
pubmed: 22179053
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
PLoS One. 2021 Apr 14;16(4):e0249424
pubmed: 33852600
Nucleic Acids Res. 2020 Jan 8;48(D1):D127-D131
pubmed: 31504780
Exp Mol Pathol. 2018 Oct;105(2):216-222
pubmed: 30170017
Neoplasia. 2018 Oct;20(10):996-1007
pubmed: 30189360
J Cell Biochem. 2018 Jun;119(6):4717-4728
pubmed: 29274284
Dis Markers. 2020 Oct 29;2020:8816070
pubmed: 33178362
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Exp Cell Res. 2013 Jun 10;319(10):1553-61
pubmed: 23588204
Biomark Res. 2013 Mar 07;1(1):16
pubmed: 24252313
Front Bioeng Biotechnol. 2020 May 13;8:460
pubmed: 32478062
J Exp Clin Cancer Res. 2012 Sep 11;31:71
pubmed: 22964035
Cell. 2012 Dec 21;151(7):1513-27
pubmed: 23260139
J Cell Physiol. 2017 May;232(5):967-975
pubmed: 27775168